Chinese Researchers Illuminate Mechanism Involved in Thalidomide’s Prevention of PF

Why Are Clinical Trials So Important for Pulmonary Fibrosis?

Clinical trials are extremely important in advancing medicine, helping to better understand how diseases begin and their progression, and to ultimately find cures or ways to prevent the disease. Clinical trials for pulmonary fibrosis (PF) are no exception and are necessary to improve treatment for patients. MORE: Seven common symptoms…

The Challenges in Sharing My Diagnosis

Sometimes, it is so discouraging to have PF. … Okay, having PF is discouraging A LOT of the time. I had a hard experience this week, as I’ve had many times before. I bet you’ve had experiences, too. Since my diagnosis with PF a little more than…

Inventiva to Present Positive Data on IVA337 in Lung Fibrosis and PH

Inventiva Pharma recently announced that their abstract titled “PAN-PPAR Agonist IVA337 is Effective in the Prevention of Experimental Lung Fibrosis and Pulmonary Hypertension” has been selected as one of the best papers that will be presented at the 15th International Workshop on Scleroderma Research. The event will take place…

9 Types of Interstitial Lung Disease

Interstitial lung disease (ILD) is not a lung disease itself but a group of several lung conditions, including idiopathic pulmonary fibrosis (IPF). You can see the difference between IPF and other interstitial lung diseases by looking at the affected lung tissue under a microscope. According to WebMD, ILDs attack the interstitium, the tissue and space around the lung’s air sacs. MORE: Interstitial lung disease remains major a diagnostic challenge This large group of diseases is known for creating progressive scarring of the interstitium which can cause progressive lung stiffness that will end up affecting the patient’s breathing…

Healthcare Advocacy Executive Is the New Leader of Pulmonary Fibrosis Foundation

William T. Schmidt, a veteran healthcare advocacy executive, is the new president and chief executive officer of the Pulmonary Fibrosis Foundation. Schmidt, who takes over Aug. 14, succeeds Patti Tuomey, who led the foundation’s fight against pulmonary fibrosis from 2010 until February 2017. “After a comprehensive search process, the…